MedCity Influencers, BioPharma

New Technology Adoption During Times of Crisis: 3 Key Lessons for Biopharma Innovators

In the face of these multifaceted threats, the need for innovative healthcare solutions becomes increasingly urgent. It underscores the vital role of the biopharmaceutical industry in not only addressing immediate health crises but also contributing to the broader resilience and well-being of humanity in times of adversity.

In the world of biopharmaceuticals, we often speak of patience, perseverance, and the relentless march of scientific progress. Developing a drug, from inception to approval, is a journey that can span decades, involving countless trials, setbacks, and breakthroughs.

But what happens when a crisis is thrust upon us? The biopharma market, it seems, becomes galvanized, and the pace of innovation and adoption accelerates exponentially. It’s in these moments when the urgency – and optimism – is palpable. We see an immediate spike in demand for bio innovation. In these cases, innovators do what we do best; we use our creativity to make the impossible possible.

Over the years, the biopharma community has witnessed this phenomenon unfold on multiple occasions and we have learned some key lessons as a result. Perhaps the most high-profile example of this is the mRNA vaccine technology acceleration during the Covid pandemic. The Covid-19 crisis served as a catalyst for innovation as this technology, which had been quietly advancing for years, suddenly took center stage. The development of Covid-19 vaccines showed us how swiftly scientific progress can be achieved when we ignite our collective will towards a singular goal. Within months, these vaccines were not only developed but also globally adopted. Innovation won the day at a time of crisis. Now, since the value of these mRNA vaccines has been validated, development is underway for non-crisis-oriented indications including HIV, Epstein-Barr virus (EBV) and even cancer.

Beyond the pandemic, the world is facing an ever-growing number of threats – both natural and man-made. Powerful earthquakes, raging floods, extreme temperatures, and fierce wildfires have killed and injured tens of thousands globally. Sadly, conflicts like the Russia-Ukraine war and the Israel-Hamas war, among others, have also added another layer of complexity to our global challenges.

In the face of these multifaceted threats, the need for innovative healthcare solutions becomes increasingly urgent. It underscores the vital role of the biopharmaceutical industry in not only addressing immediate health crises but also contributing to the broader resilience and well-being of humanity in times of adversity.

Many nations prepare for crisis by maintaining emergency medical stockpiles. These stockpiles include essential pharmaceuticals, equipment, personal protective gear, and critical supplies to address a range of urgent healthcare needs, in addition to specialized treatments for mass casualties, burns,  and more. Nevertheless, some countries opt to not proactively invest in specific resources and acquire them on a contingency basis. Unfortunately, that critical day can come unexpectedly.

For those involved in the production of biotech products that can assist during times of crisis, it is important to harness the value of your technology and work tirelessly to maximize government and health system preparedness with emergency stockpiles. We biotech innovators have the responsibility to strategically mobilize to help save lives and enhance well-being during extremely difficult situations.

Here are three lessons for biopharma innovators as the world seeks new health solutions in times of crisis:

  1. Stay focused on your long-term strategy: Unwavering commitment to your long-term vision is crucial. It might take years for your product to gain recognition, but you must remain focused, persistent and stay on course. That way you are fully prepared when the need arises. While we are unable to predict when disaster might strike, remain steadfast in developing and commercializing an effective treatment that meets the needs of individuals impacted by the crisis.
  2. Mobilize when your solution meets an immediate need: The key to successful innovation in times of crisis is recognizing when your product can truly provide a timely solution. Biotech companies must remain agile and ready to mobilize when the need arises. Be prepared to act promptly when your innovation aligns with the needs of the moment. You may find your biologic suddenly become indispensable due to its ability to treat many people efficiently and effectively, reducing complexities, logistical and otherwise. Moreover, your swift response will prove pivotal in addressing the immediate medical need.
  3. Continue to educate relevant stakeholders: Biotech innovators with crisis-oriented drugs must always be proactive in educating relevant stakeholders about their products, ensuring that when the time comes, the market understands what is possible, and how it may be compatible with the overall crisis response strategies. While patiently advancing your drug’s development, take the time to educate health authorities, physicians and key industry leaders. For example, they can visit your manufacturing facility, understand the intricacies of your product, and become well-informed about its usage and benefits. As a result, when a crisis does hit, they will quickly understand the need for its mass deployment and be ready to move.

As biotech innovators, we must stay focused on our long-term objectives, remain agile to address immediate needs, and continually educate those who can make a difference. These lessons are not just crucial for our own companies but also for the countless lives that depend on the innovations we bring to the world.

During crises, our industry’s mission takes on a renewed significance. It becomes a duty to harness our scientific knowledge and technology for the acute need.  As biotech innovators, we are entrusted with the incredible responsibility of using our research, dedication, and ingenuity to make a positive difference in the world. Our ultimate success is the profound, life-altering impact we have on those who depend on our innovations. In this, we find our true purpose and our most rewarding measure of success.

Photo: phive2015, Getty Images

Ofer Gonen is CEO of MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. Prior to his CEO appointment in 2022, Mr. Gonen served as CEO of Clal Biotechnology Industries Ltd. (TASE: CBI), Israel’s leading life science investment company, as well as a managing partner at the Anatomy Medical Technologies Fund. Mr. Gonen previously served as the General Manager of Biomedical Investments Ltd., a managing partner at Arte Venture Group, and held a variety of executive positions in the industry. Mr. Gonen received a B.Sc. in Physics, Mathematics and Chemistry from the Hebrew University of Jerusalem, and an M.A. in Economics and Finance from Tel Aviv University, with distinction. He graduated the prestigious “Talpiot” program of the Israeli Defense Forces.

This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.